What benefits are associated with CJC-1295 DAC?

CJC-1295 DAC is studied for: GH and IGF-1 elevation studied in a single-dose human PK trial, sustained GHRH-receptor agonism via albumin binding, extended plasma half-life relative to short-acting GHRH analogs, body-composition and GH-axis research contexts, subcutaneous administration in published research. This reflects the research literature catalogued on PeptideBase — educational only, not medical advice.

Educational use only — not medical advice

Research library

CJC-1295 DAC benefits

From the PeptideBase research library. Educational only — not medical advice.

Studied effects

GH and IGF-1 elevation studied in a single-dose human PK trial
sustained GHRH-receptor agonism via albumin binding
extended plasma half-life relative to short-acting GHRH analogs
body-composition and GH-axis research contexts
subcutaneous administration in published research

Mechanism

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.